Tamar Polonsky to Atherosclerosis
This is a "connection" page, showing publications Tamar Polonsky has written about Atherosclerosis.
Connection Strength
1.973
-
Highlights in ASCVD Primary Prevention for 2021. J Am Heart Assoc. 2022 07 05; 11(13):e025973.
Score: 0.596
-
Breast Arterial Calcification: Expanding the Reach of Cardiovascular Prevention. Circulation. 2017 02 07; 135(6):499-501.
Score: 0.410
-
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. JAMA Cardiol. 2024 Sep 01; 9(9):808-816.
Score: 0.173
-
Impact of aspirin dose according to race in secondary prevention of atherosclerotic cardiovascular disease: a secondary analysis of the ADAPTABLE randomised controlled trial. BMJ Open. 2024 08 07; 14(8):e078197.
Score: 0.172
-
Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease. J Am Heart Assoc. 2024 Feb 20; 13(4):e026921.
Score: 0.167
-
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial. Diabetes Care. 2024 Jan 01; 47(1):81-88.
Score: 0.165
-
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors. J Am Heart Assoc. 2023 10 17; 12(20):e030385.
Score: 0.163
-
Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines. Circulation. 2015 Sep 08; 132(10):916-22.
Score: 0.092
-
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med. 2021 05 27; 384(21):1981-1990.
Score: 0.034